GenSpera to Present at the BIO Investor Forum

GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage oncology drug discovery company developing a naturally occurring toxin in a targeted delivery system for solid tumors, announces that President and CEO Craig Dionne, Ph.D., is scheduled to present a corporate overview at the 14^th Annual BIO Investor Forum on October 21, 2015 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time). The conference is being held at Parc 55 San Francisco hotel in San Francisco.

A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.stockpr.com/genspera. A replay of the presentation will be available for 90 days.

About BIO Investor Forum

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering™ meetings.

About GenSpera

GenSpera, Inc. is an oncology drug discovery and development company. Its lead drug candidate, mipsagargin, demonstrated positive data in a Phase 2 clinical trial in hepatocellular carcinoma (liver cancer) patients and has demonstrated highly encouraging interim data in an ongoing Phase 2 trial for glioblastoma multiforme (brain cancer). GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system for the targeted release of drug candidates within solid tumors without the side-effect profile of chemotherapeutic agents. Mipsagargin was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma.

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151014005408/en/